NeuClone has partnered with the Serum Institute of India to develop ten biosimilar Wave II and Wave III monoclonal antibodies for global registration following FDA/EMA guidelines. Presently, NeuClone and the Serum Institute have invested >$215m in facilities and development to manufacture low-cost, proven biosimilars at scale.
The partnership is aimed at developing the most cost effective and highest quality biosimilars for global distribution.
Upon completion of all clinical programs, the Serum Institute will have marketing rights for all 10 biosimilars in 140 countries across the Rest of World (RoW), while NeuClone will retain all rights in developed world markets (US, Europe etc.).
NeuClone is currently reviewing partnering opportunities for its marketing rights in developed markets.